The pediatric neuromuscular disease clinic sits at a unique intersection in contemporary medicine: it treats conditions that were uniformly progressive and untreatable two decades ago and that now exist on a spectrum from newly approved gene therapies to clinical trials enrolling actively to supportive management while disease-modifying research matures. The same afternoon clinic can contain a family whose child will be offered the most transformative single-intervention in pediatric neurology — a one-time gene replacement that has changed the natural history of spinal muscular atrophy — and a family whose child’s genetic diagnosis, while scientifically precise, does not yet have a corresponding pharmacological action. The nurse working in this setting navigates a landscape where the general public perception of “there are now treatments for these diseases” collides daily with the molecular specificity of which treatments benefit which mutations, which weight windows are still open, and which diagnoses are two or three clinical trial generations from a medication that crosses into standard of care.
Spanish-speaking families navigating the pediatric neuromuscular clinic face these complexities in a second language, often having encountered fragments of the relevant terminology in patient advocacy group posts, Facebook groups in Spanish, or bilingual brochures that convey the existence of progress without the mechanistic detail that explains who qualifies for what. The three conversations in this post take place in three Texas neuromuscular clinics and represent the three most structurally difficult communication challenges in this setting: why a child who is responding to one treatment might benefit from a different one, why a disease with FDA-approved drugs does not have a drug for this particular child’s mutation, and why a confirmed genetic diagnosis is clinically valuable even when it does not produce a prescription.
Scenario 1: Valentina Morales-Torres — Houston, Texas
Pediatric neuromuscular nurse Carmen Vargas-Herrera and the parents who cannot understand why transition from nusinersen to Zolgensma is being discussed when their daughter with SMA type 2 is making developmental gains
Valentina is three years old. She was diagnosed with spinal muscular atrophy type 2 at fourteen months after her parents noticed she was not pulling to stand at the developmental window when her older brother had done so, and a delayed motor milestone workup — triggered by her pediatrician at the fifteen-month well visit — revealed absent SMN1 copies and two copies of SMN2. She was started on nusinersen at sixteen months and has received five intrathecal doses over the subsequent twenty months. The response has been visible to her parents, to her physical therapist, and to the clinic team: Valentina can now sit independently for sustained periods, can raise both arms overhead to reach toys on a low shelf, can transfer from sitting to prone without falling, and has shown progressive improvement in standardized motor assessments.
Her parents — Rosa Morales-Fuentes, who works as a medical billing specialist at a clinic in Pasadena, and Alejandro Torres-Santos, a civil engineer — have been attentive and engaged parents from the beginning of Valentina’s care. Rosa in particular has become conversant with the SMA literature, follows several SMA parent advocacy groups online, and has a clear understanding that Valentina has SMN1 deletion SMA type 2 and that nusinersen provides benefit. They arrive at today’s eighteen-month follow-up visit having received a call from the clinic coordinator two weeks earlier indicating that at today’s visit the clinical team would be initiating a conversation about onasemnogene abeparvovec-xioi — Zolgensma — as a potential alternative treatment option.
Rosa arrived prepared. She pulled up the Zolgensma product information on her phone during the drive. Alejandro drafted a list of questions. Their core objection is coherent and logical: Valentina is making progress. The nusinersen is working. Why would you stop something that is working to try something different?
Nurse Carmen Vargas-Herrera has been working in the pediatric neuromuscular clinic at Texas Children’s for seven years, which means she has navigated this conversation as the SMA treatment landscape evolved from no treatments to nusinersen alone to nusinersen plus Zolgensma. She knows the conversation is difficult precisely because the family’s premise is not wrong — Valentina is responding to nusinersen — and the nurse must help them understand something more nuanced: that “responding” and “optimally positioned for the long term” are not always the same thing.
“Quiero empezar diciendo que tienen toda la razón en lo que observan — Valentina está respondiendo al nusinersen y el progreso es real. No vengo a decirles que algo no está funcionando, porque sí está funcionando. La conversación de hoy es diferente: es sobre si hay una opción que, además de mantener lo que el nusinersen le da, le añade algo que el nusinersen no puede darle.”
(I want to start by saying that you are completely right in what you observe — Valentina is responding to nusinersen and the progress is real. I am not here to tell you that something is not working, because it is working. Today’s conversation is different: it is about whether there is an option that, in addition to maintaining what nusinersen gives her, adds something that nusinersen cannot give her.)
Rosa looks up from her phone. “¿Qué es lo que el nusinersen no puede darle?”
(What is it that nusinersen cannot give her?)
“Para responder eso necesito explicar cómo funciona cada uno, porque son mecanismos completamente diferentes aunque los dos producen más proteína SMN en el cuerpo de Valentina. El nusinersen es lo que se llama un oligonucleótido antisentido — una molécula pequeña que entra al sistema nervioso central y se une a una región específica del ARN mensajero del gen SMN2. El gen SMN2 es una copia de respaldo del gen SMN1 que falta — lo tiene Valentina, lo tenemos todos. El problema del SMN2 es que normalmente produce proteína SMN defectuosa la mayor parte del tiempo, porque hay una diferencia de una letra en el código genético que hace que la maquinaria celular salte el exón 7 al procesar el ARN. El nusinersen bloquea esa señal de salto y le dice a la célula que incluya el exón 7, produciendo más proteína SMN funcional. Mientras el nusinersen está presente en el líquido cefalorraquídeo de Valentina, eso funciona. Cuando el nivel baja antes de la siguiente inyección, el SMN2 vuelve a su patrón defectuoso. No es que deje de funcionar totalmente entre inyecciones — sino que el efecto depende del nivel del medicamento, y el nivel fluctúa.”
(To answer that I need to explain how each one works, because they are completely different mechanisms even though both produce more SMN protein in Valentina’s body. Nusinersen is what is called an antisense oligonucleotide — a small molecule that enters the central nervous system and binds to a specific region of the SMN2 messenger RNA. The SMN2 gene is a backup copy of the missing SMN1 gene — Valentina has it, we all have it. The problem with SMN2 is that it normally produces defective SMN protein most of the time, because there is a one-letter difference in the genetic code that causes the cellular machinery to skip exon 7 when processing the RNA. Nusinersen blocks that skipping signal and tells the cell to include exon 7, producing more functional SMN protein. While nusinersen is present in Valentina’s cerebrospinal fluid, that works. When the level drops before the next injection, SMN2 returns to its defective pattern. It is not that it stops working completely between injections — but the effect depends on the drug level, and the level fluctuates.)
Alejandro leans forward. “Y el Zolgensma…”
(And Zolgensma…)
“El Zolgensma es terapia génica. En lugar de modular el gen de respaldo, pone una copia funcional del gen SMN1 directamente dentro de las neuronas motoras de Valentina — usando un vector que se llama AAV9, que tiene la propiedad de cruzar la barrera hematoencefálica con una sola inyección intravenosa. Las neuronas motoras que reciben el gen empiezan a producir proteína SMN desde su propio sistema de transcripción, para siempre, sin necesidad de medicamento adicional. Es una sola infusión. No hay inyecciones cada cuatro meses. No hay fluctuación del nivel. Las neuronas que reciben el gen producen la proteína continuamente.”
(Zolgensma is gene therapy. Instead of modulating the backup gene, it puts a functional copy of the SMN1 gene directly inside Valentina’s motor neurons — using a vector called AAV9, which has the property of crossing the blood-brain barrier with a single intravenous injection. The motor neurons that receive the gene begin producing SMN protein from their own transcription system, permanently, without the need for additional medication. It is a single infusion. No injections every four months. No level fluctuation. The neurons that receive the gene produce the protein continuously.)
Rosa puts down her phone. “¿Por qué no se lo dimos desde el principio entonces?”
(Why didn’t we give it to her from the beginning then?)
“Porque cuando Valentina fue diagnosticada, el equipo evaluó todo lo que sabíamos en ese momento y el nusinersen era la primera línea con más evidencia para SMA tipo 2 a los dieciséis meses. Valentina está respondiendo. Ese juicio clínico fue correcto para entonces. La conversación hoy es sobre el siguiente paso, no sobre si cometimos un error. Y hay una razón por la que esta conversación tiene que ocurrir ahora y no en dos años: el Zolgensma tiene un límite de peso. Está aprobado para pacientes que pesan menos de 21 kilos. Valentina hoy pesa 14 kilos. A la tasa normal de crecimiento para una niña con SMA tipo 2, va a llegar a 21 kilos probablemente alrededor de los siete u ocho años. Cuando llegue a ese peso, esa opción ya no existe.”
(Because when Valentina was diagnosed, the team evaluated everything we knew at that time and nusinersen was the first line with the most evidence for SMA type 2 at sixteen months. Valentina is responding. That clinical judgment was correct for that time. The conversation today is about the next step, not about whether we made an error. And there is a reason why this conversation must happen now and not in two years: Zolgensma has a weight limit. It is approved for patients who weigh less than 21 kilograms. Valentina today weighs 14 kilograms. At the normal growth rate for a girl with SMA type 2, she will reach 21 kilograms probably around age seven or eight. When she reaches that weight, that option no longer exists.)
Rosa and Alejandro exchange a look. “¿Se cierra la ventana?” Rosa asks quietly.
(The window closes?)
“Sí. No es solo una regla administrativa — es que el volumen de distribución del vector AAV9 y la dosis aprobada están calculados para el peso corporal de un niño pequeño. A mayor peso, la dosis que produce transducción adecuada de neuronas motoras sería mayor, con perfil de seguridad diferente. El límite de 21 kilos refleja dónde está la evidencia de seguridad y eficacia actualmente. Y hay otro elemento importante: el Zolgensma no se puede repetir. Una vez que se administra, el sistema inmune de Valentina produce anticuerpos contra el vector AAV9. Si hubiera que poner una segunda dosis por alguna razón, esos anticuerpos neutralizarían el vector antes de que llegue a las neuronas. Es una sola oportunidad. Si se usa y produce buena respuesta, excelente. Si se usa y la respuesta es parcial, no hay segunda oportunidad con el mismo enfoque.”
(Yes. It is not just an administrative rule — it is that the distribution volume of the AAV9 vector and the approved dose are calculated for the body weight of a small child. At higher weight, the dose that would produce adequate motor neuron transduction would be higher, with a different safety profile. The 21-kilogram limit reflects where the safety and efficacy evidence currently stands. And there is another important element: Zolgensma cannot be repeated. Once it is administered, Valentina’s immune system produces antibodies against the AAV9 vector. If a second dose were needed for any reason, those antibodies would neutralize the vector before it reaches the neurons. It is a single opportunity. If used and it produces a good response, excellent. If used and the response is partial, there is no second chance with the same approach.)
Alejandro crosses his arms. “¿Y el nusinersen?”
(And nusinersen?)
“Si deciden no usar el Zolgensma ahora, el nusinersen continúa exactamente como está. Valentina sigue en las inyecciones cada cuatro meses, sigue respondiendo, sigue progresando. No estamos diciendo que hay que parar el nusinersen. La decisión es sobre si agregar la terapia génica ahora, mientras la ventana está abierta, versus continuar solo con el nusinersen y dejar cerrar la ventana del Zolgensma cuando Valentina llegue al límite de peso. Esta es una decisión que el equipo de neuromuscular presenta como opción — no como obligación. Hay familias en nuestra clínica que han tomado los dos caminos. El equipo puede explicarle los datos de seguridad del Zolgensma en pacientes que ya están en nusinersen, que es exactamente la situación de Valentina, si quieren revisarlos juntos.”
(If you decide not to use Zolgensma now, nusinersen continues exactly as it is. Valentina stays on the injections every four months, continues responding, continues progressing. We are not saying nusinersen must stop. The decision is about whether to add gene therapy now, while the window is open, versus continuing with nusinersen alone and letting the Zolgensma window close when Valentina reaches the weight limit. This is a decision that the neuromuscular team presents as an option — not an obligation. There are families in our clinic who have chosen both paths. The team can explain the safety data for Zolgensma in patients who are already on nusinersen, which is exactly Valentina’s situation, if you would like to review them together.)
Rosa is quiet for a moment. “¿Por qué no nos lo explicaron así desde el principio?”
(Why didn’t they explain it to us like this from the beginning?)
“Porque la situación de Valentina a los dieciséis meses era diferente. La conversación sobre Zolgensma en SMA tipo 2 con respuesta a nusinersen es relativamente reciente, y el momento correcto para presentarla es cuando la ventana de peso está lo suficientemente lejos como para que haya tiempo de deliberar, pero lo suficientemente cercana como para que sea urgente. Ese momento es ahora. No en un año cuando tenga menos tiempo, y no hace dieciocho meses cuando era prematuro.”
(Because Valentina’s situation at sixteen months was different. The conversation about Zolgensma in SMA type 2 with nusinersen response is relatively recent, and the right moment to present it is when the weight window is far enough away that there is time to deliberate, but close enough that it is urgent. That moment is now. Not in a year when there will be less time, and not eighteen months ago when it was premature.)
Alejandro unfolds his arms. He looks at his daughter playing on the exam table, reaching for a toy above her head in a motion she could not have done fourteen months ago. The conversation has shifted from “why would you change something that is working” to “what is the optimal long-term strategy given a one-time-only opportunity with a biological deadline.” That reframe is the work the nurse came to do.
Scenario 2: Sebastián García-Espinoza — San Antonio, Texas
Pediatric neuromuscular nurse Ana Fuentes-Cruz and the parents who cannot understand why their son with Duchenne muscular dystrophy cannot access an FDA-approved exon-skipping therapy
Sebastián is nine years old. He was diagnosed with Duchenne muscular dystrophy at age six after his kindergarten teacher noted that he had difficulty getting up from the floor — the Gowers’ sign that every DMD parent learns to recognize in retrospect, after the diagnosis. Genetic testing confirmed a deletion of exons 14 through 20 of the dystrophin gene, producing an out-of-frame mutation and absent dystrophin on muscle biopsy immunofluorescence. He was started on deflazacort at diagnosis and has remained ambulatory at age nine with a six-minute walk test of 348 meters, FVC 98 percent predicted, and no clinical evidence of cardiomyopathy on most recent echocardiogram. He sees the DMD clinic at UT Health San Antonio every four months.
His parents — Gabriela García-Morales, an elementary school librarian, and Diego Espinoza-Santos, who works in pharmaceutical warehouse distribution — are engaged and well-informed parents who have participated in every Cure Duchenne webinar they could access in the past three years. Diego, in particular, has deep familiarity with the exon-skipping landscape: he can name eteplirsen, golodirsen, and viltolarsen; he knows the term “exon skipping”; and he arrived at today’s visit with a single focused question that has been growing in urgency for the six months since he attended a DMD advocacy webinar where a physician discussed FDA-approved exon-skipping therapies.
“Sé que hay medicamentos aprobados por la FDA para el DMD. Sé que eteplirsen, golodirsen, viltolarsen — todos están aprobados. Mi hijo tiene DMD confirmado genéticamente. ¿Por qué no puede tomar uno de esos medicamentos?”
(I know there are FDA-approved medications for DMD. I know that eteplirsen, golodirsen, viltolarsen — all are approved. My son has genetically confirmed DMD. Why can’t he take one of those medications?)
Nurse Ana Fuentes-Cruz has heard this question dozens of times, always from parents who have done exactly what Diego has done: learned the vocabulary, understood the landscape in broad strokes, and arrived at a gap that the vocabulary does not bridge. She respects the question. Diego is not confused about whether these drugs exist. He is asking about specificity, and the answer requires going into the gene itself.
“La pregunta de Diego es exactamente la correcta — y quiero explicarla porque la respuesta no es que el exón-skipping no funciona. Es que funciona de una manera muy específica que hace que solo ciertos pacientes con ciertas eliminaciones del gen sean elegibles para cada medicamento. Vamos a empezar por cómo funciona el gen de la distrofina.”
(Diego’s question is exactly the right one — and I want to explain it because the answer is not that exon-skipping does not work. It is that it works in a very specific way that makes only certain patients with certain gene deletions eligible for each medication. Let’s start with how the dystrophin gene works.)
Diego pulls out his notebook. “Estoy listo.”
(I’m ready.)
“El gen de la distrofina — el gen DMD — es el gen más grande en el genoma humano. Tiene 79 partes funcionales que se llaman exones. Esos exones se ensamblan en secuencia para producir el ARN mensajero que las células musculares usan para fabricar la proteína distrofina. La distrofina es la proteína que conecta el interior de la célula muscular con la membrana celular — sin distrofina, la membrana de la célula muscular se rompe con el ejercicio y la célula muere gradualmente. El DMD ocurre porque hay una eliminación de uno o más exones que produce lo que se llama una mutación fuera de marco. El código genético funciona en grupos de tres letras — codones. Si se eliminan exones de una manera que produce un número de letras que no es múltiplo de tres, el marco de lectura se desplaza y aparece una señal de parada prematura en el ARN. La maquinaria celular deja de fabricar distrofina en ese punto, muy antes de completar la proteína.”
(The dystrophin gene — the DMD gene — is the largest gene in the human genome. It has 79 functional parts called exons. Those exons are assembled in sequence to produce the messenger RNA that muscle cells use to manufacture dystrophin protein. Dystrophin is the protein that connects the interior of the muscle cell to the cell membrane — without dystrophin, the muscle cell membrane ruptures with exercise and the cell dies gradually. DMD occurs because there is a deletion of one or more exons that produces what is called an out-of-frame mutation. The genetic code works in groups of three letters — codons. If exons are deleted in a way that produces a number of letters that is not a multiple of three, the reading frame shifts and a premature stop signal appears in the RNA. The cellular machinery stops making dystrophin at that point, well before completing the protein.)
Gabriela leans in. “¿Y el exón-skipping lo corrige?”
(And exon skipping corrects it?)
“El exón-skipping lo corrige de una manera específica. Usa oligonucleótidos antisentido — moléculas pequeñas de ARN modificado — que se unen al pre-ARN mensajero antes de que sea procesado, y bloquean la señal para incluir un exón específico. La maquinaria de corte y empalme de la célula entonces salta ese exón. Si el exón correcto se salta, la eliminación de Sebastián más el exón saltado produce una versión del ARN que está dentro de marco — el número de letras es múltiplo de tres, no hay señal de parada prematura, y la célula fabrica una proteína distrofina más corta pero parcialmente funcional. Es la proteína que produce la forma más leve — la distrofia muscular de Becker — donde los pacientes a menudo siguen caminando décadas más que en el DMD.”
(Exon skipping corrects it in a specific way. It uses antisense oligonucleotides — small modified RNA molecules — that bind to the pre-messenger RNA before it is processed, and block the signal to include a specific exon. The cell’s splicing machinery then skips that exon. If the right exon is skipped, Sebastián’s deletion plus the skipped exon produces a version of the RNA that is in frame — the number of letters is a multiple of three, there is no premature stop signal, and the cell makes a shorter but partially functional dystrophin protein. It is the protein that produces the milder form — Becker muscular dystrophy — where patients often continue walking decades longer than in DMD.)
Diego writes in his notebook. “Entonces el medicamento salta un exón para arreglar el marco.”
(So the medication skips an exon to fix the frame.)
“Exactamente. Pero — y aquí está la parte que explica por qué Sebastián no es elegible — el exón que hay que saltar para arreglar el marco depende de qué exones están eliminados. El eteplirsen salta el exón 51. Eso funciona para pacientes cuya eliminación está en los exones 45 al 50, o 47 al 50, o 49 al 50, o solo el 50 — porque saltando el exón 51 sobre esas eliminaciones, el resultado es que el marco queda dentro. El golodirsen y el viltolarsen saltan el exón 53. Eso funciona para eliminaciones en los exones 45 al 52, o 47 al 52, o 50 al 52, o solo el 52. El casimersen salta el exón 45. Eso funciona para eliminaciones del exón 44. Si usted tiene una eliminación fuera de esas combinaciones, saltar esos exones específicos no arregla su marco de lectura — no hace nada útil, o produciría una proteína igualmente no funcional.”
(Exactly. But — and this is the part that explains why Sebastián is not eligible — the exon that must be skipped to fix the frame depends on which exons are deleted. Eteplirsen skips exon 51. That works for patients whose deletion is in exons 45 through 50, or 47 through 50, or 49 through 50, or only exon 50 — because skipping exon 51 over those deletions produces a result where the frame is in frame. Golodirsen and viltolarsen skip exon 53. That works for deletions in exons 45 through 52, or 47 through 52, or 50 through 52, or only exon 52. Casimersen skips exon 45. That works for deletions of exon 44. If you have a deletion outside those combinations, skipping those specific exons does not fix your reading frame — it does nothing useful, or would produce an equally nonfunctional protein.)
Diego looks at the sheet in front of him. “¿Y la eliminación de Sebastián?”
(And Sebastián’s deletion?)
“Sebastián tiene eliminación de los exones 14 al 20. Esa región del gen — los exones del 1 al 30 — está completamente separada de los exones 44 al 53 que los medicamentos aprobados actualmente corrigen. Saltar el exón 51 sobre la eliminación de Sebastián no produce ningún cambio en el marco de lectura de su mutación. Son partes del gen completamente distintas. La familia de eteplirsen, golodirsen, viltolarsen y casimersen fue desarrollada y aprobada específicamente para las eliminaciones en el extremo central del gen — los hotspots de deleción del exón 45 al 55 — que son los más frecuentes y los primeros en llegar a ensayos clínicos. Las eliminaciones en la región del exón 14 al 20, como la de Sebastián, son menos frecuentes y todavía no tienen medicamentos aprobados.”
(Sebastián has a deletion of exons 14 through 20. That region of the gene — exons 1 through 30 — is completely separate from exons 44 through 53 that currently approved medications correct. Skipping exon 51 over Sebastián’s deletion produces no change in the reading frame of his mutation. They are completely different parts of the gene. The family of eteplirsen, golodirsen, viltolarsen, and casimersen was developed and approved specifically for deletions in the central end of the gene — the deletion hotspots around exons 45 through 55 — which are the most frequent and the first to reach clinical trials. Deletions in the exon 14 through 20 region, like Sebastián’s, are less frequent and do not yet have approved medications.)
Gabriela puts her hand on Diego’s arm. He is quiet for a moment. “¿Hay ensayos clínicos?”
(Are there clinical trials?)
“Sí. El campo de exón-skipping para DMD está avanzando hacia regiones del gen menos cubiertas, incluyendo exones en la parte del gen donde está la eliminación de Sebastián. Hay también el avance de las micro-distrofinas — terapias génicas que entregan una versión acortada pero funcional de la distrofina para todos los pacientes con DMD independientemente de la eliminación específica — que están en ensayos clínicos avanzados ahora mismo. Nuestro coordinador de investigación clínica va a revisar los ensayos activos para los que Sebastián podría calificar y lo vamos a contactar en las próximas semanas con lo que encontremos. La elegibilidad de Sebastián para ensayos no depende de si su eliminación coincide con los medicamentos aprobados — los ensayos de micro-distrofina, por ejemplo, están diseñados para el genoma completo de DMD.”
(Yes. The exon-skipping field for DMD is advancing toward less covered regions of the gene, including exons in the part of the gene where Sebastián’s deletion is. There is also the advance of micro-dystrophins — gene therapies that deliver a shortened but functional version of dystrophin for all patients with DMD regardless of the specific deletion — which are in advanced clinical trials right now. Our clinical research coordinator will review the active trials for which Sebastián might qualify and will contact you in the coming weeks with what we find. Sebastián’s eligibility for trials does not depend on whether his deletion matches the approved medications — micro-dystrophin trials, for example, are designed for the full DMD genome.)
Diego closes his notebook. He arrived expecting to argue for access to something that exists. He is leaving with a different frame: the drugs he read about exist and work, but they are mutation-specific, and his son’s mutation is in a region of the gene that the first wave of exon-skipping therapies does not cover — while the second wave of trials, specifically the micro-dystrophin gene therapies, may cover him regardless of which exons are deleted.
“¿El deflazacort sigue igual?” Gabriela asks.
(Deflazacort continues the same?)
“Sí. El deflazacort no es una cura — preserva la función muscular al reducir la inflamación en el músculo y ralentizar el ciclo de daño y regeneración. Sebastián está respondiendo bien — su función pulmonar está preservada, su corazón está bien en el ecocardiograma, sigue caminando. Eso no cambia mientras trabajamos en la parte de ensayos clínicos. Son dos pistas paralelas.”
(Yes. Deflazacort is not a cure — it preserves muscle function by reducing inflammation in the muscle and slowing the cycle of damage and regeneration. Sebastián is responding well — his lung function is preserved, his heart is good on echocardiogram, he continues walking. That does not change while we work on the clinical trials piece. They are two parallel tracks.)
Scenario 3: Sofía Espinoza-Morales — Dallas, Texas
Pediatric neuromuscular nurse Elena Herrera-Vargas and the parents who cannot understand why their daughter’s CMT1A genetic diagnosis comes without a treatment
Sofía is twelve years old. She was referred to the pediatric neuromuscular clinic at Children’s Health Dallas nine months ago by her orthopedic surgeon, who performed bilateral percutaneous Achilles tendon lengthening for progressive pes cavus and bilateral foot drop at age eleven and noted in the operative report that the deformity was severe for her age and that a hereditary neuropathy should be ruled out. Subsequent evaluation — nerve conduction studies showing significantly reduced median motor conduction velocity of 23 meters per second with prolonged distal latencies and reduced amplitudes, EMG showing chronic denervation changes in distal muscles, and genetic testing — confirmed the diagnosis: Charcot-Marie-Tooth disease type 1A, caused by PMP22 duplication on chromosome 17p12. Her parents received the genetic result three weeks ago by phone from the genetic counselor and were told the clinic visit today would include a treatment discussion.
Her parents — Natalia Espinoza-Cruz, a dental hygienist, and Marco Morales-Torres, who manages a chain of car washes in the Dallas area — arrived today with three months of accumulated expectation: a confirmed genetic cause should lead to a targeted treatment. Marco, in particular, spent the prior evening researching CMT1A treatments online in Spanish and found references to gene therapy research and to clinical trials but could not determine whether any of them were available for Sofía now. He is not angry. He is confused in a way that has a specific shape: how can it take three months of testing to identify precisely what is wrong with our daughter’s genes, and then there is nothing to prescribe?
Nurse Elena Herrera-Vargas enters the room knowing that Sofía is sitting in the corner of the exam room reading on her phone, that her parents have been processing a significant diagnosis for three weeks, and that the conversation about CMT1A management requires reframing what “the diagnosis is valuable” means when it does not produce a medication bottle.
“Antes de hablar sobre el manejo, quiero preguntarles qué entendieron del resultado genético cuando llamó la consejera genética, porque quiero partir desde donde están ustedes.”
(Before talking about management, I want to ask you what you understood from the genetic result when the genetic counselor called, because I want to start from where you are.)
Natalia answers. “Que Sofía tiene CMT tipo 1A. Que viene de una duplicación del gen PMP22. Que es progresiva y heredada. Y que hoy nos iban a explicar el tratamiento.”
(That Sofía has CMT type 1A. That it comes from a duplication of the PMP22 gene. That it is progressive and hereditary. And that today they were going to explain the treatment.)
Marco nods. “Tres meses de pruebas. Tenemos la respuesta exacta. Esperaba un medicamento.”
(Three months of tests. We have the exact answer. I was expecting a medication.)
Elena nods. This response — the expectation that precision in diagnosis maps to precision in pharmacology — is the most common frame families bring to the first CMT management visit.
“Entiendo completamente esa expectativa, y quiero ser directa con ustedes: hoy no voy a salir de esta sala con una prescripción de un medicamento que trate la causa del CMT1A de Sofía, porque ese medicamento no existe todavía. Eso es la verdad y no quiero suavizarla. Pero quiero explicarles por qué el diagnóstico que acaban de recibir es útil de cuatro maneras concretas — no de manera general, sino de cuatro maneras específicas que van a cambiar el cuidado de Sofía durante los próximos años. Porque si solo escuchan “no hay tratamiento” van a salir de aquí pensando que los tres meses fueron un ejercicio inútil, y eso no es cierto.”
(I understand that expectation completely, and I want to be direct with you: I am not going to leave this room today with a prescription for a medication that treats the cause of Sofía’s CMT1A, because that medication does not exist yet. That is the truth and I do not want to soften it. But I want to explain to you why the diagnosis you just received is useful in four concrete ways — not in a general way, but in four specific ways that will change Sofía’s care over the coming years. Because if you only hear ‘there is no treatment’ you are going to leave here thinking that the three months were a useless exercise, and that is not true.)
Marco leans back. “Cuatro cosas. Las escucho.”
(Four things. I’m listening.)
“La primera: pronóstico exacto. El CMT1A es una neuropatía periférica desmielinizante que progresa lentamente durante décadas. La mayoría de los pacientes — la gran mayoría — siguen caminando toda su vida, aunque con más debilidad distal y cambios ortopédicos con los años. El arco de la enfermedad de Sofía es muy diferente al de otras neuropatías periféricas hereditarias que tienen el mismo cuadro clínico pero causas genéticas distintas — algunas de esas formas progresan más rápidamente. El CMT1A específicamente tiene un pronóstico que ahora podemos describir con precisión: lento, predecible, con vigilancia anual de función pulmonar, función cardíaca, velocidades nerviosas, y estado ortopédico. Sabemos qué vigilar y cuándo.”
(The first: exact prognosis. CMT1A is a slowly progressive demyelinating peripheral neuropathy that advances over decades. The majority of patients — the great majority — continue walking throughout their lives, though with more distal weakness and orthopedic changes over the years. The disease arc for Sofía is very different from other hereditary peripheral neuropathies that have the same clinical picture but different genetic causes — some of those forms progress more rapidly. CMT1A specifically has a prognosis that we can now describe with precision: slow, predictable, with annual monitoring of pulmonary function, cardiac function, nerve conduction velocities, and orthopedic status. We know what to watch and when.)
Natalia writes in her notebook. “La segunda.”
(The second.)
“La segunda: familiares directos. El CMT1A es autosómica dominante — significa que un solo gen duplicado causa la enfermedad, y un padre con CMT1A tiene un 50% de probabilidad de transmitirlo a cada hijo. La duplicación de PMP22 de Sofía viene de algún lugar — de uno de ustedes dos, o es una mutación nueva. El consejero genético va a hablar con ustedes sobre hacerse la prueba. Si uno de ustedes tiene la misma duplicación, eso puede explicar síntomas que quizás han tenido y nunca han buscado atención, o puede identificar hermanos de Sofía que deberían ser evaluados. El diagnóstico en Sofía abre la puerta a diagnósticos en la familia.”
(The second: first-degree relatives. CMT1A is autosomal dominant — it means that a single duplicated gene causes the disease, and a parent with CMT1A has a 50 percent chance of passing it to each child. Sofía’s PMP22 duplication came from somewhere — from one of the two of you, or it is a new mutation. The genetic counselor will speak with you about getting tested. If one of you has the same duplication, that may explain symptoms you may have had and never sought care for, or it may identify siblings of Sofía who should be evaluated. The diagnosis in Sofía opens the door to diagnoses in the family.)
Marco is quiet for a moment, then: “Yo tengo los arcos de los pies muy altos. Siempre me los han comentado.”
(I have very high arches. People have always commented on them.)
“Eso es algo que el consejero genético va a explorar. Siga.” Elena writes a note. “La tercera razón por la que el diagnóstico importa es sobre medicamentos que Sofía no puede tomar — nunca, en ningún contexto. El CMT1A hace que el sistema nervioso periférico sea vulnerable a ciertas toxinas que para la mayoría de las personas son manejables. El medicamento más importante que Sofía no puede recibir es la vincristina — se usa en ciertos protocolos de quimioterapia para cánceres pediátricos. En pacientes con CMT, la vincristina puede producir una neuropatía aguda severa e irreversible. Esto no es teórico — hay casos documentados en la literatura de pacientes con CMT no diagnosticado que recibieron vincristina y sufrieron deterioro neurológico catastrófico que podría haberse prevenido si el diagnóstico hubiera sido conocido. El diagnóstico de Sofía hoy la protege de ese riesgo mañana.”
(That is something the genetic counselor will explore. Continue.) Elena writes a note. (The third reason the diagnosis matters is about medications that Sofía cannot take — ever, in any context. CMT1A makes the peripheral nervous system vulnerable to certain toxins that for most people are manageable. The most important medication Sofía cannot receive is vincristine — it is used in certain chemotherapy protocols for pediatric cancers. In patients with CMT, vincristine can produce severe and irreversible acute neuropathy. This is not theoretical — there are documented cases in the literature of patients with undiagnosed CMT who received vincristine and suffered catastrophic neurological deterioration that could have been prevented if the diagnosis had been known. Sofía’s diagnosis today protects her from that risk tomorrow.)
Natalia looks up sharply. “¿La vincristina se usa en cánceres infantiles?”
(Is vincristine used in childhood cancers?)
“Sí, en varios protocolos de leucemia y tumor de Wilms y otros. Si algún día, Dios no quiera, Sofía necesitara quimioterapia, el equipo de oncología tiene que saber que tiene CMT1A. Este diagnóstico va a estar en su expediente médico permanente. Le vamos a dar también una tarjeta de alerta médica que puede llevar con ella. Hay otros medicamentos en la lista — la nitrofurantoína que se usa para infecciones urinarias, algunos anestésicos que deben usarse con precaución — le vamos a dar la lista completa hoy.”
(Yes, in several leukemia protocols and Wilms tumor and others. If someday, God forbid, Sofía needed chemotherapy, the oncology team must know she has CMT1A. This diagnosis will be in her permanent medical record. We will also give her a medical alert card she can carry. There are other medications on the list — nitrofurantoin that is used for urinary tract infections, some anesthetics that should be used with caution — we will give you the complete list today.)
Marco writes this down. He has not said anything in two minutes. He is calculating. “¿Y la cuarta?”
(And the fourth?)
“La cuarta: ensayos clínicos. El CMT1A — el subtipo específico de Sofía — es el subtipo para el que la investigación clínica está más avanzada. Hay varias razones: es el más frecuente, la biología de la duplicación de PMP22 está bien caracterizada, y hay biomarcadores — incluyendo PMP22 en plasma — que permiten medir respuesta a tratamiento. Las terapias más prometedoras en desarrollo para CMT1A actualmente incluyen enfoques que reducen la expresión de PMP22 — porque el problema no es un PMP22 defectuoso sino un PMP22 en exceso — a través de interferencia de ARN y oligonucleótidos antisentido. Hay también terapias de remielinización y enfoques neuroprotectores. Para poder participar en esos ensayos, el diagnóstico genético confirmado de CMT1A es el requisito de elegibilidad principal. Sin ese diagnóstico, Sofía no puede ingresar. Con ese diagnóstico, cuando haya un ensayo disponible en nuestra red, ella está en la lista.”
(The fourth: clinical trials. CMT1A — Sofía’s specific subtype — is the subtype for which clinical research is most advanced. There are several reasons: it is the most frequent, the biology of PMP22 duplication is well characterized, and there are biomarkers — including plasma PMP22 — that allow response to treatment to be measured. The most promising therapies in development for CMT1A currently include approaches that reduce PMP22 expression — because the problem is not a defective PMP22 but a PMP22 in excess — through RNA interference and antisense oligonucleotides. There are also remyelination therapies and neuroprotective approaches. To be able to participate in those trials, the confirmed genetic diagnosis of CMT1A is the primary eligibility requirement. Without that diagnosis, Sofía cannot enter. With that diagnosis, when a trial is available in our network, she is on the list.)
Sofía looks up from her phone. She has been listening for the last five minutes. “¿Hay posibilidad de que haya un medicamento?”
(Is there a possibility that there will be a medication?)
“Sí. No puedo decirte cuándo. Pero CMT1A tiene más investigación activa ahora mismo que en cualquier momento anterior. Hace diez años, cuando un paciente recibía este diagnóstico, no había ensayos clínicos serios para CMT1A. Ahora los hay. El diagnóstico que tienes hoy es el que te conecta con lo que viene.”
(Yes. I cannot tell you when. But CMT1A has more active research right now than at any previous time. Ten years ago, when a patient received this diagnosis, there were no serious clinical trials for CMT1A. Now there are. The diagnosis you have today is the one that connects you to what is coming.)
Natalia puts down her pen. Marco folds his hands. Sofía goes back to her phone, but less intently. The conversation did not produce a prescription. It produced something different: a map of what the diagnosis means, what it protects against, who else in the family it implicates, and where it positions Sofía in the research pipeline. For parents who arrived expecting a medication and found none, the four concrete uses of the diagnosis — prognosis, family screening, drug contraindications, trial eligibility — is not a consolation prize. It is the answer to the question they actually had, which was not “what pill do I give her” but “what does this diagnosis mean for her life.”
What the neuromuscular nurse makes visible
The three families in these scenarios are navigating the same structural problem from three different angles: the gap between general public knowledge of treatment advances and the specific, technically-constrained reality of who benefits from which advance, when, and under what conditions. Rosa and Alejandro know that nusinersen has changed SMA — because it has, for their daughter. They do not know that the existence of a treatment that is working today does not foreclose the question of whether a different, one-time treatment should be used before a biological window closes. Diego knows that FDA-approved DMD drugs exist — because they do. He does not know that exon-skipping specificity makes those drugs applicable to 25 to 30 percent of DMD patients and that his son’s mutation is in the 70 to 75 percent not currently covered. Natalia and Marco know that genetic diagnosis is the goal of three months of testing. They do not know that a confirmed genetic diagnosis can be clinically actionable in four concrete ways even when the pharmacological action it ideally points toward does not yet exist.
The pediatric neuromuscular nurse is the clinician who closes these gaps in language families can carry home. The closing requires technical specificity — weight limits, exon numbers, gene locations, drug mechanisms — delivered in bilingual clinical conversation without jargon becoming a barrier. The SMA nurse who explains the nusinersen-Zolgensma decision must make the weight window concrete and the AAV9 non-reuse constraint real. The DMD nurse who explains exon-skipping eligibility must make the 79-exon gene and the reading-frame logic visible enough that “your son’s deletion is in a different part of the gene” is specific rather than dismissive. The CMT nurse who explains the absence of a curative medication must name the four concrete benefits of the diagnosis or risk the family concluding that three months of genetic testing produced nothing actionable.
This is precision communication for precision medicine: the therapeutic options are specific, the language about them must be equally specific, and the nurse working in the pediatric neuromuscular clinic is doing that work in two languages for families whose children’s care depends on understanding it correctly.
Internal links for further reading
For related pediatric specialty conversations involving neurological conditions, genetic diagnosis, and ongoing disease management: Spanish for pediatric neurology clinic nurses covers the broader outpatient pediatric neurology clinic conversations — epilepsy, migraine, developmental delay — providing the neurological vocabulary that underlies the motor neuron and peripheral nerve discussions in the neuromuscular clinic, including the explanations of nerve conduction physiology that are foundational to the CMT discussion in this post. Spanish for pediatric genetics clinic nurses covers the genetic diagnosis conversations that directly precede and accompany the neuromuscular clinic visits in this post — the CMT1A result interpretation, PMP22 duplication explanation, and autosomal dominant inheritance counseling that Sofía’s family received from the genetics team, including the family screening conversations about first-degree relatives. Spanish for pediatric physical medicine and rehabilitation clinic nurses covers the DMD energy economics, spasticity management, and assistive device conversations that directly intersect with the Sebastián scenario in this post — including the power wheelchair energy conservation discussion for DMD that is the companion to the treatment eligibility conversation in the neuromuscular clinic. Spanish for pediatric palliative care clinic nurses covers the advanced SMA and DMD conversations that occur when disease progression reaches the stage requiring ventilatory support and goals-of-care discussions — the conversations that occur years after the treatment decision conversations in this post for families whose children’s disease progresses despite optimal management. For the vocabulary foundation underlying all of these conversations, the 50 essential clinical Spanish phrases PDF covers the intake, assessment, and explanation phrases used in every specialty encounter. Browse the full ClinicaLingo blog for the complete library of pediatric and adult specialty conversations, or practice the communication skills with interactive scenario practice.